🇺🇸 MIRZOTAMAB in United States

51 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 51

Most-reported reactions

1. Diarrhoea — 10 reports (19.61%)
2. Pneumonitis — 6 reports (11.76%)
3. Abdominal Pain — 5 reports (9.8%)
4. Dyspnoea — 5 reports (9.8%)
5. Neutrophil Count Decreased — 5 reports (9.8%)
6. Gastrointestinal Inflammation — 4 reports (7.84%)
7. Hypoxia — 4 reports (7.84%)
8. Mucosal Inflammation — 4 reports (7.84%)
9. Oral Pain — 4 reports (7.84%)
10. Pleural Effusion — 4 reports (7.84%)

Source database →

Frequently asked questions

Is MIRZOTAMAB approved in United States?

MIRZOTAMAB does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MIRZOTAMAB in United States?

Marketing authorisation holder not available in our data.